Stage IVb bladder cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- Stage IV includes T4b, NO,MO/any T NI, MO/ any T N2 MO,/ any T N3 MO/ any T any N M1 : T4b: Tumor invades the pelvic wall, abdominal wall. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension. N3: Metastasis in a lymph node more than 5 cm in greatest dimension. M1: Distant metastasis.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Stage IVb bladder cancer
- Therapeutic area
- Oncology
- stage IVb bladder cancer
- Jewett-Marshall stage D2 bladder cancer
- Jewett-Marshall stage D2 urinary bladder cancer
- Jewett-Marshall stage D2 urinary bladder carcinoma
- stage IVB bladder cancer
- stage IVB urinary bladder cancer
- stage IVB urinary bladder carcinoma
- Severity
- Terminal
- Nephrology
- Oncology
- MONDO ID
- MONDO:0004182
- Parent condition
- MONDO:0004986
Related records
Broader conditions (17)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Malignant urinary system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Urinary bladder cancer
- Urinary bladder carcinoma
- Urinary bladder disorder
- Urinary bladder neoplasm
- Urinary system disorder
- Urinary system neoplasm
Trials (1,215)
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- [68Ga] NOTA-SGC8 in the Staging of Bladder Cancer
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
- 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
- 3 Tesla MRI in Patients With Bladder Cancer
- 3 Ultrasound Guided Plane Blocks for Perioperative Analgesia in Patients Undergoing Radical Cystectomy
- 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
- A Beta-only IL-2 ImmunoTherapY Study
- A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
- A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.